• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma (P1.177)
Conclusions:Therapies with TTF plus TBC demonstrates superior OS benefit for recurrent GBM with moderate, but manageable side effects. A prospective study of TTF plus TBC for recurrent GBM is warranted.Study Supported by: Dr. Marnie Rose FoundationDisclosure: Dr. Zhu has received personal compensation for activities with Novocure, and Prime Oncology. Dr. Zhu has received research support from Novocure, Inc., Five Prime Therapeutics, Immuno-Cellular Inc., DEKK-TEC. Dr. Lu has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Zhu has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zhu, J.-J., Lu, G., Rao, M., Zhu, P. Tags: Neuro-oncology: Gliomas I Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - December 16, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - March 9, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Chapter 15 Vascular complications in glioma patients
Publication date: 2016 Source:Handbook of Clinical Neurology, Volume 134 Author(s): Emilie Le Rhun, James R. Perry Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the...
Source: Handbook of Clinical Neurology - March 4, 2016 Category: Neurology Source Type: research

Cn-20 * bevacizumab causing recurrent cerebral infarction in a patient with glioblastoma: a previously undocumented phenomenon
CONCLUSIONS: Here we describe a case of an ischemic stroke with radiographic correlate while on bevacizumab, with clinical improvement arrested by the development of a recurrent stroke when bevacizumab was restarted. Interestingly, the distal arteries within the stroke bed appeared somewhat attentuated, suggestive of radiation vasculopathy. This case, describing a previously undocumented phenomenon, raises the possibility of a synergistic effect of bevacizumab and radiation vasculopathy. It may be that radiation vasculoapthy alone is typically insufficient to cause ischemia, but the addition of bevacizumab may precipitate ...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Winkel, D., Voloschin, A. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study
Conclusions Bevacizumab acutely impairs microvascular function independent of blood pressure changes. Imaging of the retinal microcirculation seems a valuable tool for monitoring pharmacodynamic effects of bevacizumab. Trial registration NCT ID: NCT00740168
Source: Experimental and Translational Stroke Medicine - May 13, 2013 Category: Neurology Source Type: research